Cases Of Normal Gastric Tissues Research Articles

Expression of CyclinD1, CDC25B and p27 protein in gastric carcinoma And it s clinical significance

Background: Gastric cancer is a common digestive tract tumor in our China, with high morbidity and mortality. Similar with other tumors, the occurrence of gastric cancer was also a complex pathophysiological process, regulated by a variety of oncogenes and tumor suppressor gene. Aims and Objectives: This study aims to investigate the expression of cyclin D1, CDC25B, and p27 in gastric carcinoma and to study their relationship with the occurrence and development of gastric cancer. Materials and Methods: SP immunohistochemical and Western blot analysis were used to detect the expression of cyclin D1, CDC25B, and p27 in 42 cases of gastric carcinoma, 42 cases of paracancer, and 42 cases of normal gastric tissue and then their relationship with clinical and pathological factors was analyzed. Results: (1) The expression of cyclin D1 increased gradually in normal gastric tissue, paracancer, and gastric carcinoma (P>0.05). The expression of CDC25B was higher in gastric carcinoma (P<0.05) while p27 was lower (P<0.05). (2) The result of Western blot shows that the expression of cyclin D1 and CDC25B was higher in gastric carcinoma than that in normal gastric tissue while p27 lower in gastric carcinoma (P<0.05), same with immunohistochemical. (3) The expressions of cyclin D1 and CDC25B had correlation with lymph nodes metastasis, and p27 had correlation with degrees of pathological differentiation, invasion depth, and lymph nodes metastasis. (4) There was a positive relationship between the expression of cyclin D1 and CDC25B in same sample (r=−0.392, P<0.05). Conclusion: Expression of cyclin D1, CDC25B, and p27 protein can be helpful in the prediction of the biological behavior and prognosis of gastric carcinoma.

Expressions and its prognostic value research of MMP-11 and cathepsin-D in gastric adenocarcinoma

Objective To detect the expressions of Matrix Metalloprotein-11(MMP-11) and Cathepsin-D(Cath-D), and investigate their relationship and prognostic significance. Methods The study included 95 cases′ clinical date and postoperative specimens of gastric adenocarcinoma(North China University of Science and Technology Affiliated Hospital, 2010.01-2013.12) as observation group, 70 cases of normal gastric tissue(from observation group) as control group.Expressions of MMP-11 and Cath-D were detected by IHC methods in two groups. Results The positive rate of MMP-11 was 51.6%(49/95) in observation group, 5.7%(4/70)in control group(χ2=38.884, P<0.05). The positive rate of Cath-D was 73.7%(70/95) in observation group, 28.6%(20/70) in control group(χ2=33.082, P<0.05). The positive rate of MMP-11 was correlated with metastasis and vascular invasion(χ2=7.193、15.566, P<0.05). The positive rate of Cath-D was correlated with maximal diameter, lymph node metastasis, vascular invasion and proliferation index(χ2=7.431、5.654、6.569、6.801, P<0.05). There was positive relationship between MMP-11 and Cath-D in observation group(r=0.46, P<0.05). The expressions of MMP-11 and Cath-D were correlated with prognosis in gastric adenocarcinoma(P<0.05). Conclusion The higher expressions and synergistic effect of MMP-11 and Cath-D may promote the occurrence and development in gastric adenocarcinoma.The joint detection of MMP-11 and Cath-D may be helpful to predict the prognosis of gastric adenocarcinoma. Key words: Gastric adenocarcinoma; MMP-11; Cath-D; Prognosis

Expression of RRM1 in gastric adenocarcinoma and its relationship with clinical pathological characte-ristics

Objective To investigate the expression of human ribonucleotide reductase large subunit M1 (RRM1) in the patients with gastric adenocarcinoma and its clinical significance. Methods The expre-ssions of RRM1 were detected in 88 cases of gastric adenocarcinoma and 20 cases of normal gastric tissues by immunohistochemical method. The correlations between the expression of RRM1 and clinicopathological characteristics were analyzed. Results The positive expression rate of RRM1 in gastric adenocarcinoma was 83.0% (73/88). And RRM1 was negative in the entire normal gastric tissues. The positive expression of RRM1 was not associated with patient's age (χ2=0.352, P=0.553), gender (χ2=0.493, P=0.482), depth of tumor infiltration depth (χ2=0.007, P=0.933), lymph nodes metastasis (χ2=0.121, P=0.728) and distant metastasis (P=0.415). But it was related to the degree of tumor differentiation (χ2=7.740, P=0.021) and clinical stage (χ2=5.733, P=0.017). Conclusion The expression of RRM1 is positive expression in most gastric adenocarcinoma, and is associated with the degree of tumor differentiation and clinical stage. It is of great significance to detect the expression of RRM1 in gastric adenocarcinoma for confirming the diagnosis and judging malignant degree of the tumor. It also may have potential value in choosing the best therapeutic scheme and estimating prognosis. Key words: Stomach neoplasms; Immunohistochemistry; Ribonucleotide reductase large subunit M1

Expression and Clinical Significance of Cytoskeleton microtubule-associated - Tau in gastric carcinoma

Background and Objectives: Microtubules, the main components of spindles in the mitotic phase, can provide the suitable conditions for unlimited proliferation of tumor cells. Cytoskeleton microtubule-associated-Tau accelerates the progress of malignant tumor through microtubules. Currently, the expression of Cytoskeleton microtubule-associated-Tau in gastric cancer and the relationship between clinical pathological factors research has not yet been reported, so the report aims to elucidate the features of Cytoskeleton microtubule-associated-Tau expression in normal gastric tissue and gastric carcinoma tissue.Materials and Methods: The expressions of Cytoskeleton microtubule-associated protein-Tau protein and Cytoskeleton microtubule-associated protein-Tau mRNA were investigated in 60 cases of gastric carcinoma (cases) and 10 cases of normal gastric tissues (controls). Immunohistochemistry and RT-PCR were respectively used to detect the expression of Cytoskeleton microtubule-associated protein-Tau protein and Tau mRNA in the normal and carcinomatous gastric tissues.Results: The expressions of both cytoskeleton microtubule-associated protein-Tau protein and Tau mRNA in the carcinomatous gastric tissue were higher than in the normal gastric tissue (P&lt;0.05). Likewise, both biomarkers were expressed significantly lower in the well-differentiated and moderately-differentiated gastric carcinoma was than in the poorly-differentiated one (P&lt;0.05). Moreover, their expressions in the gastric carcinoma without lymph node metastasis was lower than in the gastric carcinoma with lymph node metastasis (P&lt;0.05).Conclusion: The expressions of Cytoskeleton microtubule-associated-protein, Tau-protein and Cytoskeleton microtubule-associated-protein, Tau-mRNA were significantly different between the normal gastric tissue and the gastric carcinoma tissue, and were correlated with the degree differentiation and lymph node status.JCMS Nepal. 2015;11(3):6-11.

Expression of Tau Protein and Tau mRNA in gastric carcinoma

Aims and Objectives: To provide theoretical basis for the gastric carcinoma pathogenesis and the clinical targeted therapy. Materials and Methods: We detected the expression of Tau protein and Tau mRNA in 60 cases of gastric carcinoma tissues (observation group) and 10 cases of normal gastric tissues (control group). Immunohistochemisty was adopted to detect the expression of Tau protein in normal and carcinomatous gastric tissue. Tau mRNA was detected by RT-PCR in normal and carcinomatous gastric tissue. To analyse the experimental data combined clinical pathology with statistics. Results: The expression of Tau protein in carcinomatous gastric tissue was higher than that in normal gastric tissue (P&lt;0.05). The expression of Tau protein and Tau mRNA in well differentiated and moderately differentiated was lower than that in poorly differentiated gastric carcinoma (P&lt;0.05). The expression of Tau protein and Tau mRNA in gastric carcinoma without lymph node metastasis was lower than that in gastric carcinoma with lymph node metastasis (P&lt;0.05). The expression of Tau mRNA in carcinomatous gastric tissue was higher than that in normal gastric tissue (P&lt;0.05).Conclusion: Tau protein and Tau mRNA were significant differences between normal gastric tissue and gastric carcinoma, also were concerned with differentiation in grade and lymph node metastasis of gastric carcinoma.Asian Journal of Medical Sciences Vol.7(1) 2015 20-23

Expression of L1 protein correlates with cluster of differentiation 24 and integrin β1 expression in gastrointestinal stromal tumors

The present study examined 66 cases of gastrointestinal stromal tumors (GISTs), 20 cases of smooth muscle tumors, 20 cases of schwannomas and 20 cases of normal gastric tissues in order to analyze the expression of L1, cluster of differentiation (CD)24 and integrin β1 by immunohistochemical staining. Patients were subjected to follow-up, and survival data were evaluated. L1 expression was detected in 57.6% of GIST cases; this was a significantly higher percentage compared with that found in the smooth muscle tumor cases or the normal control group. CD24 and integrin β1 were also expressed at significantly higher levels in the GIST cases than in the normal control group, although no significant difference was found in the expression levels of these proteins in smooth muscle tumor or schwannoma cases. These higher levels of L1 and integrin β1 expression were associated with an increased risk of invasive GIST, and were significantly positively correlated with Ki-67 expression. CD24 expression was not associated with the risk of GIST invasion or Ki-67 expression. There were positive correlations between L1, CD24 and integrin β1 expression; however, these had no significant association with patient survival. Therefore, L1 alone or in conjunction with CD24 (L1 + CD24), or integrin β1 (L1 + integrin β1) can be considered a valuable indicator for the differential diagnosis of GIST. Furthermore, L1 and integrin β1 can be used alone or in combination to evaluate the biological behavior of GISTs. Future studies are required to evaluate the prognostic value of these markers.

Expressions and clinical significance of survivin and lymphatic vessel endothelial hyaluronan receptor 1 in gastric carcinoma

Objective To investigate the expressions and clinical significance of survivin, and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) in gastric cancers. Methods The expressions of survivin and LYVE-1 were detected with streptavidin avidin-peroxidase (SP) immunohistochemical method in 70 cases of gastric cancers and 50 cases of normal gastric tissues. The relationship between the expressions of survivin and LYVE-1 with the clinicopathological parameters was analyzed. Results The expression rate of survivin was 65.71% (46/70) in gastric cancers, and 6.00% (3/50) in normal gastric tissues, with statistically significant difference between two groups (χ2=43.048, P 0.05). The expression rate of LYVE-1 was 32.86% (23/70) in gastric cancers, and 4.00%(2/50) in gastric ulcers, with significant difference between two groups (χ2=14.726, P 0.05). There was a positive correlation between expressions of survivin and LYVE-1 in gastric cancers (r=0.271, P<0.05). Conclusions Survivin and LYVE-1 were abnormally expressed in gastric cancers with a colose relationships between two parameters. They might play important roles in tumorigenesis and progression of a gastric cancer. Key words: Stomach neoplasms/ME; Antigens, CD44/ME; Microtubule-associated proteins/ME

Involvement of phosphatase of regenerating liver-3 and E-cadherin in the process of the lymph node metastasis of gastric cancer

Objective To investigate the relationship between phosphatase of regenerating liver-3 (PRL-3) and E-cadherin with lymph node metastasis of gastric cancer, survival and prognosis. Methods The expression of PRL-3 and E-cadherin in 53 cases of gastric cancer tissues and 30 cases of normal gastric tissues was examined by immunohistochemical method. The relationship between PRL-3 and E-cadherin with the pathological parameters was statistically analyzed. Results PRL-3 was not expressed in normal gastric mucosa, and the positive expression of PRL-3 in gastric cancer tissues was 45. 3%(24/53).E-cadherin existed in most glandular cells of the cytoplasmic membrane, and the positive expression of E-cadherin in gastric cancer tissues was 54. 7%(29/ 53).The expression of PRL-3 was correlated with lymph node metastasis(P< 0. 01), Goseki grade(P< 0. 01), Borrmann classification(P< 0. 01) and infection of Helicobacter pylori(P< 0. 05).The expression of E-cadherin was correlated with lymph node metastasis(P< 0. 01), Borrmann classification(P< 0. 01) and infection of Helicobacter pylori(P< 0. 01).The expression of Lauren's type, PRL-3 expression and E-cadherin were independent predictive factors of survival in patients with gastric cancer. Conclusion The expression of PRL-3 and E-cadherin was related with lymph node metastasis, and two proteins were the independent predictors of survival in gastric cancer patients. Key words: Gastric cancer; Phosphatase of regenerating liver-3; E-cadherin; Lymph node metastasis

Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma

To investigate the expression of distal-less homeobox 2 (DLX2) in gastric adenocarcinoma and its clinicopathological significance. Gastric adenocarcinoma tissues were obtained from gastrectomy specimens of 129 patients from the Department of Surgery and Pathology, the Second Affiliated Hospital of Kunming Medical University. Sixty cases of normal gastric tissues were collected from gastrectomy specimens of adjacent gastric cancer margins greater than 5 cm. Patient diagnosis was established pathologically, and no patient had received chemotherapy or radiotherapy before surgery. All tissue specimens were formalin-fixed and paraffin-embedded. Immunohistochemistry was carried out to investigate the expression of DLX2 in 129 gastric adenocarcinoma tissues and 60 adjacent normal tissues. The immunostaining reaction was semiquantitatively evaluated based on the proportion of positive cells and the median staining intensity in normal gastric epithelial cells or tumor cells. All patients had follow-up records for more than 5 years. Correlations of DLX2 expression with clinicopathological features and prognosis of patients with gastric adenocarcinoma were analyzed. All statistical analyses were performed using the SPSS 17.0 software. The positive expression of DLX2 was detected in 68 (52.7%) cases of 129 gastric adenocarcinoma tissues and 14 (23.3%) cases of 60 adjacent normal tissues. The difference in DLX2 expression between gastric adenocarcinoma tissues and adjacent normal tissues was statistically significant (χ² = 14.391, P < 0.001). Moreover, high expression of DLX2 was detected in 48 (37.2%) cases of 129 human gastric cancer tissues, but not in adjacent normal tissues. The expression of DLX2 correlated with the size of tumor (P = 0.001), depth of invasion (P = 0.008), lymph node metastasis (P = 0.023) and tumor-node-metastasis stages (P = 0.020), but was not correlated with age, gender, histological differentiation and distant metastasis. The Kaplan-Meier survival analysis revealed that survival time of patients with high DLX2 expression was significantly shorter than that with low DLX2 expression. However, the multivariate analysis showed that invasion depth (P < 0.001), lymph nodes metastasis (P = 0.001) and distant metastasis (P < 0.001) were independent prognostic factors for patients with gastric adenocarcinoma, but DLX2 expression, tumor location and tumor size were not. These results suggest that increased expression of DLX2 may correlate with the advanced stage of gastric adenocarcinoma, and it may contribute to tumor development.

Expression and significance of matrix metallproteinase-25 in gastric carcinoma

Objective To investigate the expression and clinical significance of matrix metallproteinase-25 (MMP-25) in gastric carcinoma.Methods The expression of MMP-25 in 40 cases of normal gastric tissue,40 cases of atrophic gastritis and and 40 cases of gastric carcinoma was detected by using immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) separately.Results The expression rate of MMP-25 protein in gastric carcinoma and atrophic gastritis was significantly higher than in the normal gastric tissues (95.0％ and 82.5％ vs.22.5％,P＜0.05),and that of MMP-25 mRNA showed the same trend as the former (0.328 ± 0.005 and 0.175 ± 0.002 vs.0.103 ± 0.004,P ＜0.05).The expression of MMP-25 was significantly correlated with the clinicopathologieal factors such as depth of invasion,lymph node metastasis and tumor sizes (P ＜ 0.05),but not with age,gender,clinical stage and differentiation (P ＞0.05).Conclusion The MMP-25 is expressed distinctly in gastric carcinoma.MMP-25 may be involved in tumorigenesis and metastasis of gastric carcinoma,and expected to be an important biomarker for gastric carcinoma,which could provide clues for clinical diagnosis of gastric carcinoma. Key words: Matrix metallproteinase-25 ; Gastric carcinoma; Metastasis

The Role of SPARC Protein Expression in the Progress of Gastric Cancer

We aimed to investigate the expression of SPARC (secreted protein, acidic and rich in cysteine) in gastric cancer and its relationship with tumor angiogenesis and cancer cells proliferation. Protein expression of SPARC, VEGF, CD34 and Ki-67 in 80 cases of gastric cancer and 30 cases of normal gastric tissue was evaluated by immunohistochemistry. CD34 staining was used as an indicator of microvessel density (MVD). Ki-67 labeling Index (LI) indicated cancer cells proliferation. Statistical analysis was used to investigate its relationship with clinical characteristics, tumor angiogenesis and cancer cells proliferation. SPARC expression was mainly in the stromal cells surrounding the gastric cancer cells, and was statistically significant differences between gastric cancer and normal gastric tissue (P < 0.05). Both the expression of SPARC and VEGF were related to differentiation degree, clinical stage, Lauren classification and lymph node metastasis (P < 0.05). Expression of SPARC was significantly negatively correlated with the expression of VEGF and MVD in gastric cancer tissues. Expression of SPARC was also negatively correlated with Ki-67-LI. Our findings suggest that both the expression of SPARC and VEGF are closed to tumor angiogenesis in gastric cancer, SPARC inhibited tumor angiogenesis but VEGF promoted tumor angiogenesis. SPARC also inhibited cells proliferation of gastric cancer.

In vivo and in vitro expression of the RASAL1 gene in human gastric adenocarcinoma and its clinicopathological significance

Recent studies have suggested that the RAS protein activator like-1 (RASAL1) is a potential tumor suppressor, which is found to be reduced in certain human cancers. Its downregulation is involved in the progression of malignancies. However, whether or not RASAL1 plays a role in the development of gastric cancer remains to be determined. Our study aimed to clarify the role of RASAL1 in the progression of gastric adenocarcinoma. The expression of RASAL1 in primary gastric adenocarcinoma tissue specimens was determined by immunohistochemistry. The expression of RASAL1 mRNA and protein was detected by RT-PCR and western blotting in gastric adenocarcinoma cell lines with varying differentiation statuses, including well-differentiated MKN-28, moderately differentiated SGC-7901 and poorly differentiated BGC-823, respectively. A normal gastric epithelial cell line, GES-l, was used as the control line. The immunohistochemical results revealed that the expression of the RASAL1 protein was mainly observed in the cytoplasm. Among 50 cases of gastric adenocarcinoma tissues, 12 cases were identified as (-), 23 cases (+), 13 cases (++) and 2 cases (+++). Among 50 cases of normal gastric tissues, 16 cases were (++) and 34 cases (+++). The expression of the RASAL1 protein was found to be decreased in the gastric adenocarcinoma tissue compared with normal gastric tissue (p<0.01). Moreover, in the gastric carcinoma tissues, the expression of RASAL1 was correlated with carcinoma diameter, differentiation grades, invasive depth, lymph node metastasis and TNM. Additionally, the RASAL1 mRNA and proteins were decreased in the three gastric adenocarcinoma cell lines compared with the normal gastric epithelial cell line GES-l. In addition, the downregulation of RASAL1 correlated with the differentiation status of cancer cell lines. Based on the above investigation, we conclude that expression of the RASAL1 gene is decreased in gastric carcinoma tissues and cell lines. The results indicate that RASAL1 may be important in the tumorigenesis and development of gastric carcinoma.

Expression and clinical significance of selenium binding protein 1 in gastric cancer

Objective To detect the expression of selenium binding protein 1 ( SBP1 ) in gastric cancer cell line SGC7901, BGC823, normal gastric epithelial cell line GES-1, gastric cancer tissues and normal gastric tissues, explore the relationship between SBP1 and pathologic features, and discuss the feasibility of SBP1 as an diagnostic marker of gastric cancer. Methods The clinical data of 135 patients with gastric cancer who were admitted to Zhongnan Hospital of Wuhan University from 2006 to 2007 were retrospectively analyzed. The expression of SBP1 in the gastric cancer tissues and 16 cases of normal gastric tissues were detected by immunohistochemistry. The mRNA and protein expressions of SBP1 of SGC7901, BGC823 and GES-1 were determined by Western blot and RT-PCR. All data were analyzed by using chi-square test and one-way analysis of variance.Results The mRNA expressions of SBP1 in BGC823 and SGC7091 were 0. 120 ± 0. 020 and 0. 133 ± 0. 015,respectively, which were significantly lower than 0. 907 ± 0. 015 in GES-1 ( F = 2106. 462, P ＜ 0.05 ). The protein expression of SBP1 in BGC823 and SGC7901 were 0.253 ±0.015 and 0.273 ±0.015 ,respectively, which were significantly lower than 0.877 ±0.025 in GES-1 ( F = 1026. 758, P ＜0.05 ). A strong positive reaction of SBP1 was observed in 3 cases of gastric cancer tissues and 16 cases of normal gastric tissues. The decrease of the protein expression of SBP1 was correlated with clinical stages of the patients ( x2 = 12. 629, P ＜ 0.05 ), rather than the sexes, ages, tumor histological types, tumor differentiation, infiltration depths and lymph node metastasis (x2 =2. 142, 0.860, 1.838, 5.001,4.858, 1.994, P＞0. 05). Conclusions The decrease of SBP1 expression could be used as a marker in diagnosing gastric cancer. Down-regulation of SBP1 expression may play an important role in the genesis and prognosis of gastric cancer. Key words: Gastric neoplasms; Selenium binding protein 1; Immunohistochemistry

Relationship between let-7a and gastric mucosa cancerization and its significance

To investigate let-7a expression and analyze the correlation between let-7a and progression of gastric mucosa cancerization. The tissue microarray was constructed previously in 52 cases of human gastric carcinoma, 17 cases of chronic atrophic gastritis (atypical hyperplasia) and 11 cases of normal gastric tissue, and tissue microarrays combined with in situ hybridization were used to detect the expression of let-7a. The positive rates of let-7a in normal gastric tissue, chronic atrophic gastritis and gastric carcinoma were 90.9%, 88.2% and 86.5%, respectively, without significant differences among the groups (P > 0.05). However, an intense signal of let-7a was observed in gastric epithelial cells, whereas a less intense signal was found in gastric atypical hyperplasia epithelial cells and a weak signal in gastric carcinoma epithelial cells. The expression of let-7a decreased along with the progression of gastric mucosa cancerization (P < 0.05). In the group of gastric carcinoma, the expression of let-7a was even significantly lower in gastric carcinomas with lymph node metastasis than in those without metastasis (P < 0.05). Gastric carcinoma has relatively lower expression of let-7a. Reduced let-7a may be a fundamental factor in the formation and lymph node metastasis of gastric carcinoma.